Business Wire

Teradek Announces Sphere: Wireless 360º Video Monitoring and Streaming

Del

Teradek today announced the release of Sphere, a revolutionary new product for the 360º-video production market. Sphere offers real-time monitoring and live streaming of panoramic video content-in high definition.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160418006556/en/

Teradek Sphere chassis (Photo: Business Wire)

Teradek Sphere chassis (Photo: Business Wire)

“What we’ve heard from 360º content creators is the need for an effective wireless monitoring solution and an ability to share content live with others around the world,” said Nicol Verheem, CEO of Creative Solutions. “Our answer is Sphere, the world’s smallest and most flexible system for wirelessly monitoring and live-streaming 360º video content.”

Sphere is a unique combination of hardware and software featuring a patent-pending video processing platform for iOS and OSX. By dynamically adjusting each camera’s white balance, tint, exposure and lens distortion in real-time, Sphere is able to display and stream a consistent panoramic video.

Sphere’s hardware interface features four HDMI inputs and a built-in H.264 encoder that can encode up to 10Mbps, providing a realistic 360º-video experience. When connected via Ethernet to a wireless access point, Sphere streams in real-time to Apple laptops and iOS devices where users can record or view the live 4K (4x1080p) content in 3 different ways:

Perspective Mode -- Maneuver your iOS device in any direction to explore your 360º-video content as it is being shot. As you move your iOS device, the camera feed moves with it, showing you footage from any angle in which you point your tablet or smartphone.

Panoramic Mode -- Pan and zoom across all 4 video feeds stitched together into a panorama.

Headset Mode -- Experience your live 360º content as it was intended for your audience.

For remote viewing, the Sphere app can be used to live stream to any compatible 360º online video platform, including Wowza and YouTube.

Sphere is on display at the NAB show, April 18 - 21, at booth C6025. You can watch Sphere stream Teradek’s NAB Live Show with the free NAB VR application for iOS devices or by visiting www.NABLiveShow.com. Learn more about Sphere at: http://sphere.teradek.com.

ABOUT TERADEK

Teradek manufactures wireless video devices for remote video capture, wireless camera control, real-time monitoring, color correction and webcasting. For complex IP video systems, Teradek's cloud-based workflow management platform allows users to remotely operate a fleet of Teradek encoders in real-time from anywhere in the world. All Teradek products are designed and manufactured in the USA.

ABOUT CREATIVE SOLUTIONS

Creative Solutions is a part of the Vitec Group focused on empowering creatives by harnessing the rapid march of technological development into innovative and inspiring products and services. Comprising industry-leading brands Paralinx, Offhollywood, SmallHD and Teradek, Creative Solutions has facilities in Brooklyn, Irvine, Los Angeles and Raleigh-Durham.

www.teradek.com
www.twitter.com/teradek
www.facebook.com/teradek

Contact information

Teradek
Michael Gailing
mike@teradek.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom